Osteoporosis in women: the bone health statistics that matter after 50

A 62-year-old woman trips on a curb and fractures her wrist. It seems like bad luck. But when her doctor orders a bone density scan, the results show a T-score of -2.8 at the lumbar spine. She has osteoporosis. Her bones had been thinning for years. The fracture was not an accident. It was the first visible symptom of a disease that had been progressing silently since menopause.

Osteoporosis is a disease of low bone density and structural deterioration that makes bones fragile enough to break from minor falls or, in severe cases, from coughing or bending over. It affects an estimated 10 million Americans, and 80% of them are women. The condition is common and costly. It is often undiagnosed, and largely preventable.

Why osteoporosis is a women's health issue

Osteoporosis is not exclusively a female condition, but it is overwhelmingly one. Of the approximately 10 million Americans with osteoporosis, 8 million are women. An additional 44 million have low bone density (osteopenia), which places them at elevated fracture risk. The majority of those 44 million are also women.

The fundamental reason is estrogen. Estrogen is a key regulator of bone remodeling: the continuous cycle of bone breakdown and formation that maintains skeletal integrity. When estrogen levels drop at menopause, bone breakdown accelerates while bone formation remains roughly constant. The result is net bone loss, and it happens fast.

Women also start with lower peak bone mass than men. Peak bone density is typically reached between ages 25 and 30. Men, on average, have larger, denser bones. When the age-related decline begins, women start from a lower baseline and lose density at a steeper rate during the menopausal transition.

A 2014 analysis by Wright and colleagues, published in the Journal of Bone and Mineral Research, used NHANES data to estimate that 16.0% of women aged 50 and older have osteoporosis at the femoral neck (hip), compared to 4.4% of men. When osteopenia is included, 61.3% of women over 50 have compromised bone density.

The postmenopausal bone loss window

The 5 to 7 years immediately following menopause represent the period of most rapid bone loss. During this window, women lose an average of 2% to 3% of bone density per year at the spine and 1% to 2% per year at the hip. Over the full window, total bone loss can reach 20% or more.

After this rapid phase, bone loss continues at a slower rate of about 0.5% to 1% per year. The cumulative effect is significant: by age 70, a woman may have lost 30% to 40% of her peak bone density.

The rate of loss varies between individuals and is influenced by genetics, body weight, physical activity, calcium and vitamin D intake, smoking, alcohol use, and certain medications (corticosteroids, aromatase inhibitors, proton pump inhibitors). Women who experience premature menopause (before age 40) or early menopause (before age 45) face a longer window of estrogen deficiency and correspondingly higher lifetime fracture risk.

This is one of the reasons why the menopause hormone therapy discussion is relevant to bone health. Estrogen therapy during the menopausal transition preserves bone density and reduces fracture risk. That benefit has been consistently demonstrated across studies, including the Women's Health Initiative. Our menopause and hormone therapy article covers the evidence and current guidelines.

Fracture statistics

The clinical importance of osteoporosis is measured in fractures. Low bone density by itself causes no symptoms. Fractures cause the pain, disability, and loss of independence. Some kill.

The National Osteoporosis Foundation estimates that 1 in 2 women over age 50 will experience an osteoporosis-related fracture in her remaining lifetime. That is a higher probability than the combined risk of breast cancer, heart attack, and stroke. For men over 50, the figure is 1 in 4.

Approximately 2 million osteoporotic fractures occur annually in the United States. The most common sites are:

Fracture site	Estimated annual incidence	Percentage of total
Vertebral (spine)	700,000	35%
Wrist (distal radius)	400,000	20%
Hip	300,000	15%
Other (pelvis, humerus, etc.)	600,000	30%

Source: Burge et al., JBMR, 2007; National Osteoporosis Foundation estimates

Fracture risk by age group (women)

Approximate relative fracture risk based on NOF data and FRAX modeling. Individual risk varies by bone density, fall history, and other factors.

Vertebral fractures are the most common but also the most underdiagnosed. Only about one-third of vertebral compression fractures come to clinical attention. The rest cause chronic back pain, height loss, and kyphosis (the forward curvature of the upper spine sometimes called a "dowager's hump") without ever being formally identified as fractures.

The hip fracture problem

Hip fractures deserve separate attention because their consequences are severe.

Among women who sustain a hip fracture after age 50, approximately 20% to 24% will die within one year. That is higher than the one-year mortality for many cancers. Among those who survive, roughly half will not regain their previous level of function. Many will require long-term nursing care or assisted living.

A 2018 analysis by Lewiecki and colleagues, published in Osteoporosis International, tracked hip fracture trends in the United States from 2002 to 2015. Age-adjusted hip fracture rates declined during this period, driven by improved diagnosis and treatment uptake. The absolute number of hip fractures has begun rising again in recent years, though. The population of adults over 65 is growing faster than the per-capita fracture rate is declining.

Women account for approximately 75% of all hip fractures. A woman's lifetime risk of hip fracture (about 17%) is equal to her combined risk of developing breast, uterine, and ovarian cancer.

What follows a hip fracture is what makes it so hard. Surgery is almost always required. Recovery is slow. Immobility during recovery leads to muscle loss, blood clots, and pneumonia; delirium is common too. For older women living independently before the fracture, the event often marks a permanent transition to dependent living.

Who gets screened and who does not

The U.S. Preventive Services Task Force recommends bone density screening (via DXA scan) for all women aged 65 and older, and for younger postmenopausal women who have risk factors for osteoporosis. The National Osteoporosis Foundation and the International Society for Clinical Densitometry support the same guidelines.

Despite this, screening rates are low. Only about 24% of women aged 65 and older who experience a fragility fracture receive a bone density test or osteoporosis treatment within 6 months. That means 3 out of 4 women who break a bone from a low-impact fall (the clearest possible signal that their bones may be compromised) do not get evaluated for osteoporosis.

The screening gap is partly a failure of follow-up. A woman breaks her wrist. The orthopedic surgeon sets the fracture. Nobody orders a DXA scan or asks about bone health. She returns to her primary care doctor weeks later, and the fracture is treated as an isolated injury. The underlying osteoporosis goes unaddressed until the next fracture.

Fracture liaison services are hospital-based programs that automatically identify patients with fragility fractures and connect them to bone health assessment. They have been shown to reduce re-fracture rates by 30% to 40%. They are standard in the UK and much of Europe, and in Australia as well. In the U.S., adoption remains slow.

The economics of osteoporotic fractures

Osteoporotic fractures cost the U.S. healthcare system an estimated $19 billion annually in direct medical costs, per a 2007 analysis by Burge and colleagues that has been updated with inflation adjustments. Some more recent estimates place the figure above $20 billion.

Hip fractures account for roughly 72% of that cost. The average hospital stay for a hip fracture is 5 to 7 days. First-year costs, including surgery and post-acute care, average $40,000 to $50,000 per patient. Many patients require extended nursing facility care, which adds substantially to the total.

The economic projections are concerning. As the U.S. population ages, the number of osteoporotic fractures is expected to rise significantly. Burge et al. projected that by 2025, annual fracture incidence would exceed 3 million and costs would approach $25 billion. Osteoporosis prevention through screening and treatment is a fiscal priority as well as a clinical one.

Calcium, vitamin D, and what the evidence says

Calcium and vitamin D are the nutritional foundations of bone health. The evidence for both is solid, though less simple than supplement marketing suggests.

Calcium. The National Osteoporosis Foundation recommends 1,000 mg of calcium daily for women aged 19 to 50 and 1,200 mg daily for women over 50. The preferred source is food: dairy products, fortified plant milks, leafy greens, canned sardines with bones, and tofu made with calcium sulfate. Supplements can fill the gap when dietary intake falls short.

A meta-analysis published in The BMJ in 2015 raised questions about whether calcium supplements increase cardiovascular risk. The data is mixed. Subsequent analyses have not confirmed a clear causal link, but most professional guidelines now recommend food-based calcium when possible and limiting supplement doses to 500 to 600 mg at a time for better absorption. The NOF continues to recommend supplementation when dietary intake is inadequate.

Vitamin D. Vitamin D is necessary for calcium absorption. Without adequate vitamin D, even sufficient calcium intake cannot maintain bone density. The recommended daily intake is 600 IU for adults under 70 and 800 IU for adults 70 and older. Many clinicians target blood levels of 30 ng/mL or higher and adjust the dose to hit that mark. An estimated 42% of U.S. adults are vitamin D deficient, with higher rates among women, older adults, people with darker skin, and those living at northern latitudes.

Vitamin D supplementation at 700 to 800 IU daily has been shown to reduce hip fracture risk by approximately 26% in meta-analyses. The greatest benefit shows up in populations with low baseline vitamin D levels.

As a dietitian, I want to be direct about something: supplements are not a substitute for a diet that supports bone health. Protein and magnesium matter too, as do potassium and vitamin K. A diet that regularly includes dairy or fortified alternatives, leafy vegetables, lean protein, and whole grains provides a broader nutritional foundation than any pill. Our nutrition guide covers dietary patterns relevant to hormonal and metabolic health more broadly.

Treatment options and the treatment gap

Multiple effective medications exist for osteoporosis. The treatment gap is not about lack of options. It is about underuse.

Bisphosphonates (alendronate, risedronate, zoledronic acid) are the most commonly prescribed osteoporosis medications. They work by slowing bone breakdown. Alendronate reduces vertebral fracture risk by about 44% and hip fracture risk by about 40% over 3 to 4 years in clinical trials. Zoledronic acid, given as an annual IV infusion, reduces vertebral fracture risk by 70% and hip fracture risk by 41%.

Denosumab (Prolia) is a biologic that inhibits RANKL, a protein involved in bone breakdown. It reduces vertebral fracture risk by 68%, hip fracture risk by 40%, and is given as a subcutaneous injection every 6 months. A critical caveat: discontinuing denosumab leads to rapid bone loss and an increased risk of vertebral fractures, so transition planning is essential.

Anabolic agents (teriparatide, abaloparatide, romosozumab) build new bone rather than just slowing breakdown. They are reserved for patients with severe osteoporosis or those who have failed other treatments. Romosozumab, approved in 2019, reduces vertebral fracture risk by 73% at 12 months and is given as monthly injections for one year, followed by an anti-resorptive agent.

Despite these effective options, the treatment gap is wide. Studies consistently show that only 20% to 30% of patients diagnosed with osteoporosis are actually prescribed and consistently taking medication. After hip fracture, the treatment rate is similarly poor. The reasons include provider inertia, patient concerns about side effects (particularly the rare but publicized risk of atypical femur fractures with long-term bisphosphonate use), and inadequate care coordination.

Our perimenopause guide discusses the broader changes that occur during the menopausal transition, including the accelerated bone loss that makes this a critical window for prevention.

Racial and ethnic differences

Osteoporosis prevalence varies by race and ethnicity, but the disparities are not always in the direction people assume.

White and Asian women have the highest rates of osteoporosis. Among women over 50, approximately 20% of non-Hispanic white women and 20% of Asian American women have osteoporosis, compared to about 5% of non-Hispanic Black women, based on femoral neck DXA measurements from NHANES data.

Black women have higher average bone density than white women, which confers some protection against osteoporosis. That does not make Black women immune to fractures. A study by Cauley and colleagues, published in JAMA, found that Black women who do sustain hip fractures have higher post-fracture mortality rates than white women. They are also less likely to receive osteoporosis screening and treatment.

Hispanic women have intermediate bone density levels and osteoporosis rates. Their fracture risk is often underestimated by clinicians, and they are less likely to undergo DXA screening.

The FRAX fracture risk assessment tool, which is widely used to estimate 10-year fracture probability, was originally developed and validated primarily in white populations. It may underestimate fracture risk in some minority populations. Clinicians should be aware of this limitation.

Frequently asked questions about osteoporosis in women

What percentage of osteoporosis patients are women?

Approximately 80% of the estimated 10 million Americans with osteoporosis are women, according to the National Osteoporosis Foundation (now the Bone Health & Osteoporosis Foundation). The disparity is driven by lower peak bone mass, smaller bone structure, and the rapid bone loss that occurs when estrogen declines at menopause. An additional 44 million Americans have low bone density (osteopenia), with women again comprising the majority.

How much bone density do women lose after menopause?

Women lose up to 20% of their bone density in the 5 to 7 years following menopause, at a rate of 2% to 3% per year at the spine and 1% to 2% per year at the hip. After this rapid phase, bone loss continues at a slower rate of 0.5% to 1% per year. By age 70, cumulative bone loss can reach 30% to 40% of peak density. Estrogen decline is the primary driver of this accelerated postmenopausal bone loss.

How likely is a woman over 50 to break a bone from osteoporosis?

One in 2 women over age 50 will experience an osteoporosis-related fracture in her remaining lifetime. That is a higher probability than the combined lifetime risk of breast cancer plus uterine and ovarian cancer. Approximately 2 million osteoporotic fractures occur annually in the U.S. Vertebral fractures are the most common (700,000 per year), followed by wrist fractures (400,000) and hip fractures (300,000).

How much does osteoporosis cost the healthcare system?

Osteoporotic fractures cost the U.S. healthcare system an estimated $19 billion annually in direct medical costs. Hip fractures account for roughly 72% of that expense, with first-year costs per patient averaging $40,000 to $50,000. As the population ages, annual fracture-related costs are projected to exceed $25 billion. Fracture prevention through screening and treatment is substantially more cost-effective than fracture management.

How much calcium and vitamin D do women need for bone health?

The National Osteoporosis Foundation recommends 1,000 mg of calcium daily for women under 50 and 1,200 mg daily for women over 50, preferably from food sources. Vitamin D recommendations are 600 IU daily for women under 70 and 800 IU for women 70 and older. Approximately 42% of U.S. adults are vitamin D deficient. Vitamin D supplementation at 700 to 800 IU daily has been shown to reduce hip fracture risk by about 26% in meta-analyses.

When should women get screened for osteoporosis?

The USPSTF recommends DXA bone density screening for all women aged 65 and older, and for younger postmenopausal women with risk factors for osteoporosis (low body weight, family history, smoking, early menopause, long-term corticosteroid use). Despite these guidelines, only about 24% of women who experience a fragility fracture receive a bone density test or treatment within 6 months. Ask your doctor about screening if you have risk factors.